At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
IMB-1018972drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients With Type 2 Diabetes.
In Brief
A Phase 2 clinical trial evaluating IMB-1018972 for Type 2 Diabetes and 2 related conditions. Completed, enrolled 49 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction
CountriesUnited Kingdom
CollaboratorsUniversity of Oxford
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartApr 2021
Primary CompletionAug 2024
TodayJul 2026
First PostedApr 1, 2021
Enrollment StartApr 21, 2021
Primary CompletionAug 6, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.3 years ago
Interventions
IMB-1018972drug
Modified release tablet for oral administration